ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Tarsons Products Investor Presentation: Key Takeaways

Tarsons reported 21% YoY consolidated revenue growth in Q1 FY27, reaching ₹110.2 cr, driven by domestic and export recovery despite margin pressure from raw material costs and new facility expenses.

Highlights
MarginsEBITDA margins compressed by 340 bps YoY to 23.6% (consolidated).
Demand visibilityEncouraging customer enquiries suggest sustained demand momentum in coming quarters.

Growth

Consolidated revenue grew 21% YoY; Domestic up 17%, Exports up 29%. Standalone PAT fell 81% to ₹0.7 cr.

Outlook

New Panchla cell culture lines commissioning by Q2FY27; revenue contribution from new facilities expected to scale in FY28-29.

Risks

High raw material prices due to supply chain disruptions; higher depreciation and finance costs from new facilities.

Last quarter's promises, checked

Delivered

  • Guided full commissioning of capex in H1 FY27 → delivered Q2 FY27 timeline (= BEAT)
  • Guided domestic business resilience → delivered 17% YoY growth (= BEAT)
  • Guided export recovery from Q4 lows → delivered 29% YoY growth (= BEAT)

Partly delivered

  • Guided gradual revenue scale-up from new plants → delivered 21% consol growth but PAT fell 81% (= PARTIAL)

Missed

  • Guided stable gross margins (71-72%) → delivered 23.6% EBITDA margin with high RM pressure (= MISS)
Source

Investor Presentation filed with BSE, NSE: TARSONS. Summary written with AI assistance from the document.

Read the document ↗

Tarsons Products Ltd: key numbers

Share price
₹325.10
Market cap
₹1,730 Cr
Revenue (annual)
₹422.5 Cr
Net profit (annual)
₹14.32 Cr
P/E (TTM)
155.9×Sector 54.5×
Promoter holding
47.30%+0.00% QoQ
FII holding
0.55%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Tarsons Products Ltd

All →